Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

PROGNOSTIC SIGNIFICANCE OF CARBONIC ANHYDRASE IX (CA IX) IN BREAST CANCER PATIENTS TREATED WITH RADIOTHERAPY (CROSBI ID 574181)

Prilog sa skupa u časopisu | sažetak izlaganja sa skupa | međunarodna recenzija

Beketić-Oresković, Lidija ; Ozretić, Petar ; Rabbani, Zahid ; Jackson, Isabel ; Šarčević, Božena ; Levanat, Sonja ; Marić, Petra ; Vujašković, Željko PROGNOSTIC SIGNIFICANCE OF CARBONIC ANHYDRASE IX (CA IX) IN BREAST CANCER PATIENTS TREATED WITH RADIOTHERAPY // Radiotherapy and oncology / Overgaard, Jens (ur.). 2011. str. S303-S304

Podaci o odgovornosti

Beketić-Oresković, Lidija ; Ozretić, Petar ; Rabbani, Zahid ; Jackson, Isabel ; Šarčević, Božena ; Levanat, Sonja ; Marić, Petra ; Vujašković, Željko

engleski

PROGNOSTIC SIGNIFICANCE OF CARBONIC ANHYDRASE IX (CA IX) IN BREAST CANCER PATIENTS TREATED WITH RADIOTHERAPY

Purpose: The purpose of this study was to analyse tumor expression of carbonic anhydrase IX (CA IX) to evaluate this hypoxia marker as potential prognostic parametar for overall survival (OS) and relapse-free (RFS) survival in breast cancer patients treated with radiotherapy. Materials: Immunohistochemical expression of CA IX was analyzed on paraffin-embedded tumor tissues, obtained during surgery from forty female breast cancer patients. The extent of CA IX expression was used to assess prognostic implication of this hypoxic marker on overall survival (OS) and relapse-free survival (RFS) in breast cancer patients. Relation of CA IX expression and clinicopathological parametars was determined. All patients received standard adjuvant treatment including radiotherapy. Fisher’s exact test, chi-square test, Spearman rank correlation coefficient, Kaplan-Meier univariate method and the Cox proportional hazards regression model were used for statistical analysis. Results: Patients with high CA-IX expression (above cut-off value) had a higher occurrence of relapse (P=0.002). High CA-IX expression was significantly associated with shorter RFS (P<0.001, hazard ratio (HR) 0.21) and shorter OS (P<0.001, HR 0.19). High expression of CA-IX was associated with moderate to severe tumor necrosis (P=0.004) and positive lymph nodes (P=0.003). Among the lymph node negative patients and those with grade II tumors it was possible to differentiate patients with better and worse prognosis based on the expression level of hypoxia marker CA IX. Lymph node negative patients with high CA-IX expression had worse RFS (P=0.031, HR 0.14) and OS (P=0.005, HR 0.05). Within the subgroup of patients with grade II tumors, those patients with high CA IX expression showed shorter OS (P=0.046, HR 0.28). Multivariate analysis proved that high CA-IX expression was strong independent prognostic indicator for shorter OS (HR 4.14, 95% CI 1.28-13.35, P=0.018) and shorter RFS (HR 3.99, 95% CI 1.38-11.59, P=0.011). Conclusions: According to this study, elevated expression of CA IX was an independent prognostic factor for decreased RFS and OS and a significant marker for tumor aggressiveness in breast cancer patients. We also showed that the extent of CA IX expression was a strong prognostic factor among node-negative breast cancer patients and those with grade II tumors, for which additional prognostic parameters are sometimes needed to determine optimal adjuvant therapy.Since hypoxia plays a significant role in tumor sensitivity to radiotherapy, the implication of CA IX as a predictive marker remains to be determined.

breast cancer ; Carbonic Anhydrase IX (CA-IX) ; prognostic tumor marker ; radiotherapy

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

S303-S304.

2011.

nije evidentirano

objavljeno

Podaci o matičnoj publikaciji

Radiotherapy and oncology

Overgaard, Jens

Elsevier

0167-8140

Podaci o skupu

ESTRO Anniversary: GEC-ESTRO • EIOF • 11th BIENNIAL ESTRO

poster

08.05.2011-12.05.2011

London, Ujedinjeno Kraljevstvo

Povezanost rada

Kliničke medicinske znanosti

Indeksiranost